As of March 31, 2025, cash, cash equivalents and marketable securities totaled $197.9 million compared to cash, cash equivalents and marketable securities of $231.5 million as of December 31, 2024. The decrease in cash is related to funding ongoing operations. Cash is expected to support current clinical and operational activities into early 2027.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- Acumen presented results from pTau217 assay in Phase 2 ALTITUDE-AD trial
- Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges
- Acumen Pharmaceuticals’ Promising Alzheimer’s Strategy Earns Buy Rating with Revised Price Target
- Acumen price target lowered to $11 from $15 at H.C. Wainwright
- Acumen price target lowered to $10 from $12 at BofA